



NVTH Symposium – 5 & 6 April 2017  
Golden Tulip Hotel Westduin – Koudekerke, Zeeland

**Wednesday 5 April**

- 11.30 – 12.30 Registration and Lunch
- 12.30 – 13.00 **Keynote Lecture I**  
Suzanne Cannegieter (LUMC): *“Prevention of venous thrombosis: is prediction the future?”*  
Moderator: Ton Lisman (UMCG)
- 13.00 – 14.00 **Session I: Novel Clinical Insights**  
Moderators: Karina Meijer (UMCG) and Luuk Scheres (AMC/LUMC)

**DEVELOPMENT AND VALIDATION OF A PRACTICAL TWO-STEP PREDICTION MODEL FOR POST-THROMBOTIC SYNDROME**

Elham Amin<sup>1,2,3</sup>, Sander M.J. van Kuijk<sup>3</sup>, Manuela A. Joore<sup>3</sup>, Hugo ten Cate<sup>1,2</sup>, Arina J. ten Cate-Hoek<sup>1,2</sup>. <sup>1</sup>Laboratory for Clinical Thrombosis and Haemostasis, Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands; <sup>2</sup>Department of Internal Medicine, Maastricht University Medical Centre, the Netherlands; <sup>3</sup>Department of Clinical Epidemiology and Medical Technology assessment, School for Public Health and Primary Care, Maastricht University, Maastricht, the Netherlands.

**PATIENTS WITH CANCER-ASSOCIATED THROMBOSIS BENEFIT FROM ANTICOAGULANT TREATMENT BEYOND 6 MONTHS**

I.T. Wilts<sup>1</sup>, J. Trujillo-Santos<sup>2</sup>, P.W. Kamphuisen<sup>3</sup>, Luis Hernández-Blasco<sup>4</sup>, Marina Lumbierres<sup>5</sup>, María del Carmen Díaz-Pedroche<sup>6</sup>, Manuel Alejandro Lorente<sup>7</sup>, Juan Bosco López-Sáez<sup>8</sup>, Maurizio Ciammaichella<sup>9</sup>, M.M. Monreal<sup>10</sup>; And the RIETE Investigators. <sup>1</sup>Dept of Vascular Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; <sup>2</sup>Dept of Internal Medicine, Hospital Universitario Santa María de Rosel, Cartagena, Murcia, Spain; <sup>3</sup>Dept of Vascular Medicine, University Medical Center Groningen, University of Groningen, Groningen, and Tergooi Hospital, Hilversum, the Netherlands; <sup>4</sup>Dept of Pneumology, Alicante University General Hospital and Dept of Clinical Medicine, Miguel Hernandez University, ISABIAL – FISABIO, Alicante, Spain; <sup>5</sup>Dept of Pneumology, Hospital Universitari Arnau de Vilanova, Lleida, Spain; <sup>6</sup>Dept of Internal Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain; <sup>7</sup>Department of Internal Medicine, Hospital Vega Baja de Orihuela, Alicante, Spain; <sup>8</sup>Department of Internal Medicine, Hospital Universitario de Puerto Real, Cádiz, Spain; <sup>9</sup>Department of Emergency Internal Medicine, Ospedale St. John, Rome, Italy; <sup>10</sup>Dept of Internal Medicine, Hospital Universitari Germans Trias i Pujol de Badalona, Universidad Católica de Murcia, Barcelona, Spain.

**THE FACTOR V LEIDEN MUTATION IS ASSOCIATED WITH INCREASED SPERM COUNT**

T.E. van Mens<sup>1,2</sup>, U. N. Joensen<sup>3,4</sup>, Z. Bochdanovits<sup>5</sup>, A. Takizawa<sup>6</sup>, J. Peter<sup>7</sup>, N. Jørgensen<sup>3</sup>, P.B. Szecsi<sup>8</sup>, J.C.M. Meijers<sup>7,9</sup>, H. Weiler<sup>2</sup>, E. Rajpert-De Meyts<sup>3</sup>, S. Repping<sup>10</sup>, S. Middeldorp<sup>1</sup>. <sup>1</sup>Department of Vascular Medicine, Academic Medical Center, the Netherlands; <sup>2</sup>Blood Research Institute, Blood Center of Wisconsin, Milwaukee, USA; <sup>3</sup>Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Denmark; <sup>4</sup>International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, Denmark; <sup>5</sup>Department of Clinical Genetics, VU University Medical Center, Amsterdam, the Netherlands; <sup>6</sup>Department of Physiology, Medical College of Wisconsin, Milwaukee, USA; <sup>7</sup>Department of Experimental Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands; <sup>8</sup>Department of Clinical Biochemistry, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; <sup>9</sup>Department of Plasma Proteins, Sanquin Research, Amsterdam, the Netherlands; <sup>10</sup>Center for Reproductive Medicine, Academic Medical Center, Amsterdam, the Netherlands.

**CLINICAL USEFULNESS OF THE SAME-TT2R2 SCORE. A SYSTEMATIC REVIEW AND SIMULATION META-ANALYSIS**

J.H.A. van Miert<sup>1</sup>, S. Bos<sup>2</sup>, N.J.G.M. Veeger<sup>3</sup>, K. Meijer<sup>1</sup>. <sup>1</sup>Department of Haematology, University Medical Center Groningen, the Netherlands; <sup>2</sup>Department of Internal Medicine, University Medical Center Groningen, the Netherlands; <sup>3</sup>Department of Clinical Epidemiology, University Medical Center Groningen, the Netherlands.

- 14.00 – 14.30 Quiz  
Moderator: Henri Spronk (MUMC)



NVTH Symposium – 5 & 6 April 2017  
Golden Tulip Hotel Westduin – Koudekerke, Zeeland

14.30 – 15.00      Tea break

15.00 – 15.30      **Keynote Lecture II**  
Tilman Hackeng: “*To-die-for TFPI*”  
Moderator: Joost Meijers (Sanquin)

15.30 – 16.30      **Session II: Molecular mechanisms of coagulation**  
Moderators: Steven de Maat (UMCU) and Tom Plug (Sanquin)

**PLASMIN CLEAVAGE OF ADAMTS-13 ENHANCES ITS ACTIVITY**

Chantal C. Clark<sup>1\*</sup>, Mirjam M. Mebius<sup>1,2\*</sup>, Steven de Maat<sup>1</sup>, Aloysius G. M. Tielens<sup>2,3</sup>, Philip G. de Groot<sup>1</sup>, Rolf T. Urbanus<sup>1</sup>, Rob Fijnheer<sup>1</sup>, Jaap J. van Hellemond<sup>2</sup>, Coen Maas<sup>1</sup>. <sup>1</sup>Department Clinical Chemistry & Haematology, University Medical Center, Utrecht, the Netherlands; <sup>2</sup>Department Medical Microbiology & Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands; <sup>3</sup>Department Biochemistry & Cell Biology, Faculty Veterinary Medicine, Utrecht University, the Netherlands. \*These authors contributed equally.

**APC AND TFPI COFACTOR ACTIVITIES OF THROMBIN-CLEAVED PROTEIN S AND C4BP-PROTEIN S COMPLEX**

Nahla Alshaikh, Jan Rosing, Tilman Hackeng. Department of Biochemistry, Maastricht University, Maastricht, The Netherlands.

**CLEAVED KININOGEN AS A BIOMARKER FOR BRADYKININ PRODUCTION**

Z.L.M. Hofman<sup>1,2</sup>, S. de Maat<sup>1</sup>, C. Suffritti<sup>3</sup>, C.L.R. van Doorn<sup>1</sup>, D. Csuka<sup>4</sup>, A. Zanichelli<sup>3</sup>, N. Veszeli<sup>4</sup>, G. Pasterkamp<sup>1</sup>, T. René<sup>5,6</sup>, M. Cicardi<sup>3</sup>, H. Farkas<sup>4</sup>, E. Hack<sup>2</sup>, C. Maas<sup>1</sup>. <sup>1</sup>University Medical Center Utrecht, Laboratory of Clinical Chemistry and Hematology, Utrecht, The Netherlands; <sup>2</sup>University Medical Center Utrecht, Laboratory for Translational Immunology, Utrecht, The Netherlands; <sup>3</sup>Luigi Sacco Hospital Milan, University of Milan, the Department of Biomedical and Clinical Sciences, Milan, Italy; <sup>4</sup>Semmelweis University, 3rd Department of Internal Medicine, Budapest, Hungary; <sup>5</sup>Karolinska Institutet and University Hospital, the Department of Molecular Medicine and Surgery, Stockholm, Sweden; <sup>6</sup>University Medical Center Hamburg-Eppendorf, the Institute of Clinical Chemistry and Laboratory Medicine, Hamburg, Germany.

**STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF ANTICOAGULANT TIX-5, THE SPECIFIC INHIBITOR OF THE ACTIVATION OF FV BY FXA**

Anja Maag<sup>1,2</sup>, Priyanka Sharma<sup>1</sup>, Tim Schuijt<sup>1</sup>, Wilhelmina Kopatz<sup>3</sup>, Daniëlle Kruijswijk<sup>1</sup>, Arnoud Marquart<sup>4</sup>, Tom van der Poll<sup>1</sup>, Tilman Hackeng<sup>5</sup>, Gerry Nicolaes<sup>5</sup>, Joost Meijers<sup>3,4</sup>, Mettine H.A. Bos<sup>2</sup>, Cornelis van 't Veer<sup>1</sup>. <sup>1</sup>Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands; <sup>2</sup>Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands; <sup>3</sup>Experimental Vascular Medicine Department, Academic Medical Center, Amsterdam, The Netherlands; <sup>4</sup>Department of Plasma Proteins, Sanquin Research, Amsterdam, The Netherlands; <sup>5</sup>Department of Biochemistry, Maastricht University, Maastricht, The Netherlands.

16.30 – 17.30      **Van Creveld Lecture:**  
Flip de Groot (UMCU): “*The antiphospholipid syndrome. A critical review*”  
Moderator: Saskia Middeldorp (AMC)

17.30 – 17.45      Presentation NVTH Awards  
Moderators: Saskia Middeldorp (AMC) + Shirley Uitte de Willige (EMC)

18.00 – ...      Dinner and party at Kon-tiki (beach)



NVTH Symposium – 5 & 6 April 2017  
Golden Tulip Hotel Westduin – Koudekerke, Zeeland

**Thursday 6 April**

07.30 – 09.00 Breakfast

09.00 – 09.30 **Keynote Lecture III**  
Suzanne Korporaal (UMCU): *“The relation between platelets and lipids, living apart together”*  
Moderator: Mark Roest (Synapse)

09.30 – 10.30 **Session III: Platelets**  
Moderators: Rolf Urbanus (UMCU) and Judith Cosemans (MUMC)

**A POTENTIAL ROLE OF PLATELET ACTIVATION IN THE PROGRESSION OF ATRIAL FIBRILLATION**

S.C. Dólleman, H.C. de Boer and A.J. van Zonneveld. Department of Internal Medicine (Nephrology) and the Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Centre, The Netherlands.

**THE INVOLVEMENT OF  $\alpha_{IIb}\beta_3$  INTEGRIN ON THE RELEASE OF EXTRACELLULAR VESICLES AND THE CHEMOKINES CXCL4 AND CCL5 BY PLATELETS**

Alexandra.CA. Heinzmann, Tanja Vajen, Johan. WM. Heemskerk, Judith. M. Cosemans, Tilman. M. Hackeng, Rory. R. Koenen. Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.

**DIFFERENT ROLES FOR PLATELET GLYCOPROTEIN VI AND CLEC2 DURING GRAM NEGATIVE PNEUMONIA DERIVED SEPSIS**

Theodora A.M. Claushuis<sup>1</sup>, Alex F. de Vos<sup>1</sup>, Bernard Nieswandt<sup>2</sup>, Louis Boon<sup>3</sup>, Joris J.T.H. Roelofs<sup>4</sup>, O.J. de Boer<sup>4</sup>, Cornelis van 't Veer<sup>1</sup> and Tom van der Poll<sup>1,5</sup>. <sup>1</sup>Center for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; <sup>2</sup>Institute of Experimental Biomedicine, University Hospital Würzburg and Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, Würzburg, Germany; <sup>3</sup>Bioceros, Utrecht, The Netherlands; <sup>4</sup>Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; <sup>5</sup>Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

**VALIDATION OF A FLOW CYTOMETRIC PLATELET FUNCTION TEST IN A COHORT OF PATIENTS WITH A SUSPECTED PLATELET FUNCTION DISORDER**

I van Asten<sup>1</sup>, M Baaij<sup>1</sup>, J Zandstra<sup>1</sup>, A Huisman<sup>1</sup>, G Pasterkamp<sup>1</sup>, REG Schutgens<sup>2</sup>, SJA Korporaal<sup>1</sup>, RT Urbanus<sup>1</sup>. <sup>1</sup>Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, the Netherlands; <sup>2</sup>Van Creveld Clinic, University Medical Center Utrecht, the Netherlands.

10.30 – 11.00 **Additional Lecture**  
Speaker: Ton van Raan (Leiden University): *“A bibliometric view on thrombosis research: the Netherlands in international perspective”*  
Moderator: Henri Versteeg (LUMC)

11.00 – 11.30 Coffee break

11.30 – 12.00 **Keynote Lecture IV**  
Mettine Bos: *“Learning from the adaptive evolution of snake venom proteins”*  
Moderator: Kees van 't Veer (AMC)



NVTH Symposium – 5 & 6 April 2017  
Golden Tulip Hotel Westduin – Koudekerke, Zeeland

12.00 – 13.00

**Session IV: Thrombosis and bleeding disorders**

Moderators: Marieke Kruip (EMC) and Ingrid Bistervels (AMC)

**ACUTE LOWERING OF FACTOR XII INDUCES ACCELERATED SPONTANEOUS VENOUS THROMBOSIS IN MICE: NEW EVIDENCE FOR THE CONTACT SYSTEM THAT “IDLES”?**

Marco Heestermans<sup>1,2</sup>, Katrin F. Nickel<sup>3</sup>, René van Oerle<sup>4</sup>, Henri H. Versteeg<sup>1,2</sup>, Pieter H. Reitsma<sup>1,2</sup>, Tobias A. Fuchs<sup>3</sup>, Thomas Renné<sup>3</sup>, Henri M. Spronk<sup>4</sup>, Bart J.M. van Vlijmen<sup>1,2</sup>. <sup>1</sup>Eindhoven Laboratory for Experimental Vascular Medicine; <sup>2</sup>Department of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands; <sup>3</sup>Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; <sup>4</sup>Department of Internal Medicine and Biochemistry, Maastricht University, Maastricht, The Netherlands.

**ALLELE-SPECIFIC INHIBITION OF VON WILLEBRAND FACTOR P.CYS2773SER RESTORES A SEVERE MULTIMERIZATION DEFECT**

A. de Jong, R.J. Dirven, J.A. Oud, D. Tio and J. Eikenboom. Eindhoven Laboratory for Vascular and Regenerative Medicine, Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.

**MICE LACKING THE NOVEL VENOUS THROMBOEMBOLISM SUSCEPTIBILITY GENE SLC44A2 HAVE NORMAL HEMOSTASIS, BUT REDUCED FIBRIN ACCUMULATION UPON VASCULAR INJURY**

J. Tilburg<sup>1</sup>, R. Adili<sup>3</sup>, T.S. Nair<sup>2</sup>, M.E. Hawley<sup>3</sup>, B.J.M. van Vlijmen<sup>1</sup>, D.C. Tuk<sup>1</sup>, H.M. Spronk<sup>4</sup>, M. Holinstat<sup>3</sup>, T.E. Carey<sup>2</sup>, C.X. Maracle<sup>1</sup>. <sup>1</sup>Eindhoven Laboratory for Experimental Vascular Medicine, Department of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands; <sup>2</sup>Kresge Hearing Research Institute, Department of Otolaryngology/Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA; <sup>3</sup>Department of Pharmacology and Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA; <sup>4</sup>Laboratory for Clinical Thrombosis and Hemostasis, Department of Internal Medicine and Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands.

**GENES ASSOCIATED WITH VENOUS THROMBOEMBOLISM IN COLORECTAL CANCER PATIENTS**

Betül Ünlü<sup>1</sup>, Jim Crama<sup>1</sup>, Nick van Es<sup>2</sup>, Wibowo Arindrato<sup>3</sup>, Szymon M. Kielbasa<sup>3</sup>, Hans-Martin Otten<sup>4</sup>, Peter J. Kuppen<sup>5</sup>, Suzanne Cannegieter<sup>1,6</sup>, Henri H. Versteeg<sup>1</sup>. <sup>1</sup>Department of Thrombosis and Hemostasis, Eindhoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands; <sup>2</sup>Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands; <sup>3</sup>Sequence Analysis Support Core, Leiden University Medical Center, Leiden, The Netherlands; <sup>4</sup>Slotervaart Hospital, Amsterdam, The Netherlands; <sup>5</sup>Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; <sup>6</sup>Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.

13.00 – 14.00

Lunch

14.00 – 14.30

NVTH Annual meeting

14.30 – 15.00

**Keynote Lecture V**

Anske van der Bom: “Factor VIII products and inhibitory antibodies: fake or true?”

Moderator: Jan Voorberg (Sanquin)

15.00 – 16.00

**Session V: Coagulation in clinical practice**

Moderators: Roger Schutgens (UMCU) and Jelle Posthuma (MUMC)

**COMPARING PLATELET-DEPENDENT VON WILLEBRAND FACTOR ACTIVITY ASSAYS IN 661 PATIENTS WITH VON WILLEBRAND DISEASE - FROM THE WIN STUDY**

J. Boender<sup>1</sup>, J. Eikenboom<sup>2,3</sup>, J.G. van der Bom<sup>4,5</sup>, K. Meijer<sup>6</sup>, J. de Meris<sup>7</sup>, K. Fijnvandraat<sup>8</sup>, M.H. Cnossen<sup>9</sup>, B. Laros-van Gorkom<sup>10</sup>, E. Mauser-Bunschoten<sup>11</sup>, M.P.M. de Maat<sup>1</sup>, and F.W.G. Leebeek<sup>1</sup>, for the WiN Study Group. <sup>1</sup>Erasmus University Medical Center, Hematology, Rotterdam, The Netherlands; <sup>2</sup>Leiden University Medical Center, Thrombosis



## NVTH Symposium – 5 & 6 April 2017 Golden Tulip Hotel Westduin – Koudekerke, Zeeland

and Hemostasis, Leiden, The Netherlands; <sup>3</sup>Leiden University Medical Center, Einthoven Laboratory for Experimental Vascular Medicine, Leiden, The Netherlands; <sup>4</sup>Leiden University Medical Center, Clinical Epidemiology, Leiden, The Netherlands; <sup>5</sup>Sanquin Research, Jon J van Rood Center for Clinical Transfusion Medicine, Leiden, The Netherlands; <sup>6</sup>University Medical Center Groningen, Hematology, Groningen, The Netherlands; <sup>7</sup>Netherlands Hemophilia Society, Nijkerk, The Netherlands; <sup>8</sup>Emma Children's Hospital, Academic Medical Center, Pediatric Hematology, Amsterdam, The Netherlands; <sup>9</sup>Erasmus University Medical Center - Sophia Children's Hospital, Pediatric Hematology, Rotterdam, The Netherlands; <sup>10</sup>Radboud university medical center, Hematology, Nijmegen, The Netherlands; <sup>11</sup>University Medical Center Utrecht, van Creveldklinik/departement of Hematology, Utrecht, The Netherlands.

### **ORAL ANTICOAGULANTS AS MODULATORS OF ARTERIAL CALCIFICATION**

Rick H. van Gorp<sup>1,2</sup>, Armand Jaminon<sup>1</sup>, Matthias Bauwens<sup>3</sup>, Jan Bucerius<sup>3</sup>, Vincent Brandenburg<sup>4</sup>, Willi Jahnen-Dechent<sup>5</sup>, Henri M.H. Spronk<sup>1</sup>, Chris P. Reutelingsperger<sup>1</sup> and Leon J. Schurgers<sup>1</sup>. <sup>1</sup>Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands; <sup>2</sup>Nattopharma ASA, Hovik, Norway; <sup>3</sup>Department of Radiology and Nuclear Medicine, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands; <sup>4</sup>Department of Cardiology, University Hospital of the RWTH Aachen, Germany; <sup>5</sup>Helmholtz-Institute, RWTH Aachen, Aachen.

### **BLEEDING PHENOTYPE IN NON-SEVERE HEMOPHILIA A HAS A BETTER ASSOCIATION WITH THE ONE-STAGE THAN THE CHROMOGENIC ASSAY**

L.M. Schütte<sup>1</sup>, I. van Moort<sup>2</sup>, S.C.M. Stooft<sup>1</sup>, J.S. Biedermann<sup>1</sup>, M.H. Cnossen<sup>2</sup>, F.W.G. Leebeek<sup>1</sup>, M.P.M. de Maat<sup>1</sup>, M.J.H.A. Kruip<sup>1</sup>. <sup>1</sup>Department of Hematology, Erasmus University Medical Center, Rotterdam; <sup>2</sup>Department of Pediatric Hematology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam.

### **PREOPERATIVE SCREENING FOR BLEEDING DISORDERS: A COMPREHENSIVE LABORATORY ASSESSMENT OF CLINICAL PRACTICE**

Minka J.A. Vries<sup>1</sup>, Paola E.J. van der Meijden<sup>1</sup>, Gerhardus J.A.J.M. Kuiper<sup>2</sup>, Patricia J. Nelemans<sup>3</sup>, Rick J.H. Wetzels<sup>4</sup>, René van Oerle<sup>1,4</sup>, Marcus D. Lance<sup>2,5</sup>, Hugo ten Cate<sup>1,6</sup>, Yvonne M.C. Henskens<sup>1,4</sup>. <sup>1</sup>Maastricht University, Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), The Netherlands; <sup>2</sup>Maastricht University Medical Centre+ (MUMC+), Anaesthesiology, Maastricht, The Netherlands; <sup>3</sup>MUMC+, Epidemiology; <sup>4</sup>MUMC+, Central Diagnostic Laboratory; <sup>5</sup>Hamad Medical Centre, Anaesthesiology, Qatar, United Arab Emirates; <sup>6</sup>MUMC+, Internal Medicine, Maastricht, The Netherlands.

16.00 – 16.30

Results quiz, presentation Jeanne Stibbe bokaal and closure

Moderators: Saskia Middeldorp (AMC) + Shirley Uitte de Willige (EMC)